通心络与参松养心胶囊联合常规西药治疗室性心律失常患者的效果

doi:10.3760/cma.j.issn.1007-1245.2023.07.013

国际医药卫生导报 ›› 2023, Vol. 29 ›› Issue (7): 944-947.DOI: 10.3760/cma.j.issn.1007-1245.2023.07.013

通心络与参松养心胶囊联合常规西药治疗室性心律失常患者的效果

李会林

濮阳惠民医院功能科，濮阳　457000

收稿日期:2022-11-07 出版日期:2023-04-01 发布日期:2023-04-28
通讯作者: Email: xueyalia@163.com
基金资助:
河南省医学科技攻关项目（LHGJ2021003312）

Effect of Tongxinluo and Shensong Yangxin capsules combined with conventional western medicine on patients with ventricular arrhythmia

Li Huilin

Functional Department, Puyang Huimin Hospital, Puyang 457000, China

Received:2022-11-07 Online:2023-04-01 Published:2023-04-28
Contact: Email: xueyalia@163.com
Supported by:
Medical Science and Technology Project of Henan Province (LHGJ2021003312)

摘要/Abstract

摘要：

目的　探析室性心律失常患者采用通心络与参松养心胶囊联合常规西药治疗的效果。方法　本研究为随机对照试验。选择2021年1月至2022年1月濮阳惠民医院收治的室性心律失常患者138例，采用随机数字表法将患者分为对照组与观察组，各69例。对照组男37例、女32例，年龄（61.48±9.42）岁，采用常规西药治疗；观察组男34例、女35例，年龄（61.52±9.67）岁，在对照组基础上加用通心络联合参松养心胶囊治疗。比较两组患者疗效、心功能、心电图指标及不良反应发生率。采用t检验、χ²检验。结果　观察组治疗总有效率为94.20%（65/69），高于对照组69.57%（48/69），差异有统计学意义（χ²=14.118，P<0.001）。治疗1个月后，观察组左心室射血分数（LVEF）［（58.98±2.69）%］高于对照组［（53.58±2.88）%］，左心室舒张末期内径（LVEDD）［（51.69±3.47）mm］、左心室收缩末期容积（LVESV）［（77.92±11.43）mm］均低于对照组［（56.75±3.61）mm、（86.37±12.79）mm］，差异均有统计学意义（均P<0.05）。治疗1个月后，观察组房室传导时间（PR间期）［（201.28±25.25）ms］长于对照组［（186.61±20.39）ms］，心室除极到完全复极时间（QT间期）［（347.11±13.29）ms］短于对照组［（363.35±15.58）ms］，QT间期最大值-QT间期最小值（QT离散度）［（41.17±9.63）ms］低于对照组［（52.96±10.13）ms］，差异均有统计学意义（均P<0.05）。观察组不良反应发生率为5.80%（4/69），与对照组4.35%（3/69）比较，差异无统计学意义（χ²=0.151，P=0.698）。结论　对室性心律失常患者采用通心络与参松养心胶囊联合常规西药治疗可获得良好效果，能改善其心功能及心电活动，安全可靠，值得推广。

关键词:

室性心律失常, 通心络胶囊, 参松养心胶囊, 疗效

Abstract:

Objective　To explore the therapeutic effect of Tongxinluo combined with Shensong Yangxin capsules on patients with ventricular arrhythmia. Methods　It was a randomized controlled trial. A total of 138 patients with ventricular arrhythmia admitted to Puyang Huimin Hospital from January 2021 to January 2022 were selected and were divided into a control group and an observation group by the random number table method with 69 patients in each group. The control group included 37 males and 32 females, aged (61.48±9.42) years; the observation group included 34 males and 35 females, aged (61.52±9.67) years. The patients in the control group were treated with conventional western medicine, and the patients in the observation group were treated with Tongxinluo and Shensong Yangxin capsules on the basis of the control group. The curative effects, heart function, electrocardiographic indicators, and adverse reactions were compared between the two groups. t test and χ² test were used. Results　The total effective rate of the observation group was 94.20% (65/69), which was higher than that of the control group [69.57% (48/69)], with a statistically significant difference (χ²=14.118, P<0.001). After one month of treatment, the left ventricular ejection fraction (LVEF) in the observation group [(58.98±2.69)%] was higher than that in the control group [(53.58±2.88)%], while the left ventricular end-diastolic diameter (LVEDD) [(51.69±3.47) mm] and left ventricular end-systolic volume (LVESV) [(77.92±11.43) mm] were lower than those of control group [(56.75±3.61) mm and (86.37±12.79) mm], with statistically significant differences (all P<0.05). After one month of treatment, the atrioventricular conduction time (PR interval) in the observation group [(201.28±25.25) ms] was higher than that in the control group [(186.61±20.39) ms], while the time of ventricular depolarization to complete repolarization (QT interval) [(347.11±13.29) ms] and QT dispersion (maximum QT interval - minimum QT interval) [(41.17±9.63) ms] were lower than those in the control group [(363.35±15.58) ms and (52.96±10.13) ms], with statistically significant differences (all P<0.05). There was no statistically significant difference in the incidence of adverse reactions between the observation group and the control group [5.80% (4/69) vs. 4.35% (3/69)] (χ²=0.151, P=0.698). Conclusion　Tongxinluo combined with Shensong Yangxin capsules can achieve the good results in the treatment of patients with ventricular arrhythmia, which can significantly improve their cardiac function and electrical activity, and is safe and reliable, worthy of promotion.

Key words:

Ventricular arrhythmia, Tongxinluo capsules, Shensong Yangxin capsules, Curative effect

李会林.

通心络与参松养心胶囊联合常规西药治疗室性心律失常患者的效果 [J]. 国际医药卫生导报, 2023, 29(7): 944-947.

Li Huilin.

Effect of Tongxinluo and Shensong Yangxin capsules combined with conventional western medicine on patients with ventricular arrhythmia [J]. International Medicine and Health Guidance News, 2023, 29(7): 944-947.

参考文献

[1] 韩雅洁,范小倩,巩彩霞,等. 致心律失常性左室心肌病的研究进展[J]. 心血管病学进展,2021,42(4):342-346.DOI:10.16806/j.cnki.issn.1004-3934.2021.04.013.
[2] 王瑞华,李艳芬,李美凤,等. 心室复极离散度指标早期预测化疗药物诱发室性心律失常心脏毒性反应的诊断价值[J]. 中西医结合心脑血管病杂志,2022,20(14):2517-2520.DOI:10.12102/j.issn.1672-1349.2022.14.004.
[3] 汤梅. 胺碘酮联合琥珀酸美托洛尔缓释片在急诊治疗室性心律失常中的应用[J]. 山西医药杂志,2021,50(14):2155-2158.DOI:10.3969/j.issn.0253-9926.2021.14.006.
[4] 沈祥礼,李岚,姜述斌,等. 稳心颗粒联合美托洛尔对埋藏式心脏转复除颤器患者室性心律失常的疗效[J]. 中国心脏起搏与心电生理杂志,2021,35(5):426-428.DOI:10.13333/j.cnki.cjcpe.2021.05.006.
[5] 苏文文,秦义,张菀桐,等. 翁维良教授治疗频发室性早搏临证经验[J]. 天津中医药,2020,37(8):871-876.DOI:10.11656/j.issn.1672-1519.2020.08.08.
[6] 孟红梅,刘海永,张颖娜,等. 长针平刺内关结合口服参松养心胶囊治疗室性心律失常的临床研究[J]. 中国医药导报,2021,18(12):170-173.
[7] 王晓红. 参松养心胶囊联合小剂量胺碘酮治疗室性心律失常的效果及对患者心电图、血管内皮功能的影响[J]. 临床医学研究与实践,2019,4(2):119-121.DOI:10.19347/j.cnki.2096-1413.201902054.
[8] 中华医学会心电生理和起搏分会,中国医师协会心律学专业委员会. 2020室性心律失常中国专家共识(2016共识升级版)[J]. 中国心脏起搏与心电生理杂志,2020,34(3):189-253. DOI:10.13333/j.cnki.cjcpe.2020.03.001.
[9] 王雲,沈琳,马子霖,等. 室性心律失常与心率变异性的中西医研究进展[J]. 中西医结合心脑血管病杂志,2021,19(17):2939-2942.DOI:10.12102/j.issn.1672-1349.2021.17.012.
[10] 吴巧敏,汪艳丽,刘金凤,等. 刘如秀教授从五藏论治频发室性期前收缩临床经验[J]. 湖南中医药大学学报,2021,41(7):1089-1093.DOI:10.3969/j.issn.1674-070X.2021.07.020.
[11] 白杨,彭建业,曾高峰. 参松养心胶囊治疗心衰伴室性心律失常的疗效[J]. 实用中西医结合临床,2022,22(16):14-16,25.DOI:10.13638/j.issn.1671-4040.2022.16.004.
[12] 张磊,丁辉. 通心络胶囊联合沙库巴曲缬沙坦钠片治疗慢性心力衰竭的疗效及对患者心功能和炎症因子的影响[J]. 海南医学,2021,32(24):3162-3165.DOI:10.3969/j.issn.1003-6350.2021.24.010.
[13] 钟扬. 心力衰竭合并室性心律失常患者应用参松养心胶囊辅助治疗的效果[J]. 中国实用医药,2022,17(5):15-17.DOI:10.14163/j.cnki.11-5547/r.2022.05.005.
[14] 张海明,邵雅丽,王锋,等. 通心络胶囊通过调节AMPK减轻缺氧诱导的心肌细胞凋亡和炎症[J]. 中国老年学杂志,2021,41(22):5113-5116.DOI:10.3969/j.issn.1005-9202. 2021.22.068.
[15] 赵辉. 参松养心胶囊治疗慢性心力衰竭合并室性心律失常的研究进展[J]. 中国中西医结合急救杂志,2021,28(6):770-772.DOI:10.3969/j.issn.1008-9691.2021.06.031.
[16] 苟春丽,贺秀,刘永铭. 参松养心胶囊联合胺碘酮治疗心力衰竭合并室性心律失常的meta分析[J]. 中西医结合心脑血管病杂志,2020,18(23):3924-3930.DOI:10.12102/j.issn.1672-1349.2020.23.004.
[17] 薛剑,杨绍兴,高红军,等. 参松养心胶囊预防化疗药物所致心律失常的疗效分析[J]. 中国循证心血管医学杂志,2021,13(4):489-491,498.DOI:10.3969/j.issn.1674-4055.2021. 04.25.
[18] 张芸,郑平原,仪庆春,等. 参松养心胶囊治疗心力衰竭并室性心律失常的临床疗效分析[J]. 中医临床研究,2021,13(6):128-130.DOI:10.3969/j.issn.1674-7860.2021.06.044.
[19] 赵岩. 参松养心胶囊联合胺碘酮对室性心律失常患者心电图及免疫功能的影响[J]. 系统医学,2021,6(3):59-61.DOI:10.19368/j.cnki.2096-1782.2021.03.059.
[20] 付海涛. 参松养心胶囊联合普罗帕酮对室性心律失常患者心电图及免疫功能的影响[J]. 华夏医学,2021,34(1):44-47.DOI:10.19296/j.cnki.1008-2409.2021-01-012.

通心络与参松养心胶囊联合常规西药治疗室性心律失常患者的效果

Effect of Tongxinluo and Shensong Yangxin capsules combined with conventional western medicine on patients with ventricular arrhythmia

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 0

编辑推荐

Metrics